Printer Friendly

SYSTEMIX DISCOVERY OF PLURIPOTENT STEM CELLS NAMED ONE TOP 10 MEDICAL ADVANCES OF 1992

 PALO ALTO, Calif., March 30 /PRNewswire/ -- SyStemix, Inc., (NASDAQ: STMX) today announced that its isolation of the pluripotent stem cell has been cited as one of the top 10 medical advances of 1992 by the Harvard Health Letter, a publication of the Harvard Medical School.
 "The mother of all blood cells...spell big trouble for many people, including those with certain hereditary disorders, leukemia, and immune deficiencies," the Harvard authors said in the March 1993 edition. The medical advances of 1992 were evaluated and ranked by the Harvard Health Letter's physician advisory board. Members weighted the significance of research findings based on their potential for having the greatest long-range impact on human health and disease.
 "The stem cell is the only cell which not only regenerates, but gives rise to all the cells of the blood system. As such, we believe it is the key to finding a cure for a number of damaging diseases," said Linda Sonntag, Ph.D., president and CEO of SyStemix. "We were awarded a U.S. Patent for the separation of human hematopoietic stem cells from bone marrow and for their cellular composition. The company is actively working to commercialize our technology based on this important invention."
 The discovery was featured in an article published in April of 1992 in Proceedings of the National Academy of Sciences (PNAS). The study's authors are Charles Baum, M.D., Ph.D.; Irving L. Weissman, M.D.; Ann Tsukamoto, Ph.D.; Ann-Marie Buckle, Ph.D.; and Bruno Peault, Ph.D.
 SyStemix, Inc., based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human magakaryocytes and megakaryocyte progenitors.
 -0- 3/30/93
 /CONTACT: Linda Sonntag, Ph.D., president and CEO of SyStemix, Inc., 415-813-6510; or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, Inc., 212-979-9180, for SyStemix/
 (STMX)


CO: SyStemix, Inc. ST: California IN: MTC SU:

SH-LR -- NY016 -- 0868 03/30/93 08:35 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1993
Words:327
Previous Article:NATIONAL CENTER FOR MISSING AND EXPLOITED CHILDREN ENDORSES NATIONAL CHILD PHOTO ID PROGRAM
Next Article:MAGAININ PHARMACEUTICALS RECEIVES PATENT FOR SQUALAMINE
Topics:


Related Articles
Blood cells traced to a common ancestor.
SANDOZ LTD. TO ACQUIRE 60 PERCENT OF SYSTEMIX COMMON STOCK
SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES
SYSTEMIX ENTERS JOINT VENTURE WITH SANDOZ FOR GENE THERAPY AGAINST HIV
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTHS RESULTS
SYSTEMIX REPORTS FOURTH QUARTER AND TWELVE MONTHS RESULTS
SYSTEMIX PRESIDENT/CEO RESIGNS
SYSTEMIX RECEIVES REGULATORY APPROVAL TO BEGIN STEM CELL TRIALS IN U.S. AND EUROPE
SYSTEMIX ANNOUNCES ITS U.S. PHASE I/II CLINICAL TRIALS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters